行情

EGRX

EGRX

Eagle制药
NASDAQ

实时行情|Nasdaq Last Sale

55.98
-2.02
-3.48%
已收盘, 16:05 11/20 EST
开盘
57.81
昨收
58.00
最高
58.11
最低
55.57
成交量
16.18万
成交额
--
52周最高
64.94
52周最低
36.03
市值
7.65亿
市盈率(TTM)
31.43
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EGRX 新闻

  • Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.13小时前
  • Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference
  • Business Wire.21小时前
  • Eagle Pharma files for $200M mixed shelf
  • seekingalpha.5天前
  • Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors
  • Business Wire.6天前

更多

所属板块

制药
-0.37%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

EGRX 简况

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
展开

Webull提供Eagle Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。